American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Odronextamab Plus CHOP in First-Line DLBCL: Early Results From the OLYMPIA-3 Study

DLBCL Download: Emerging Insights From ASCO 2026

Odronextamab combined with CHOP shows high response rates in high-risk, frontline DLBCL, with manageable safety and low rates of severe immune toxicity. Read More ›

Tafasitamab Plus Lenalidomide and R-CHOP in High-Risk Newly Diagnosed DLBCL: Results From the Phase 3 frontMIND Study

DLBCL Download: Emerging Insights From ASCO 2026

Adding tafasitamab and lenalidomide to R-CHOP improved progression-free survival in patients with high-risk, newly diagnosed DLBCL, with a generally manageable safety profile. Read More ›

Outcomes by LymphoMAP Archetypes in Untreated DLBCL: POLARIX

DLBCL Download: Emerging Insights From ASCO 2026

Pola-R-CHP shows consistent benefit across DLBCL microenvironment subtypes, with the strongest gains seen in the high-risk FMAC group. Read More ›

Videos

Patient-Reported Outcomes Highlight Favorable Tolerability of Zongertinib in HER2-Mutant NSCLC: Insights From the Beamion LUNG-1 Trial

By Beth Sandy, MSN, CRNP, FAPO

ASCO 2025 - Non-Small Cell Lung Cancer

Patient-reported outcomes from the Beamion LUNG-1 trial showed sustained improvements in physical functioning and symptom burden, with low side effect severity, supporting zongertinib’s potential in advanced NSCLC. Read More ›

Videos

Safety and Efficacy of Sevabertinib (BAY 2927088) in HER2-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): Results From the Phase I/II SOHO-01 Trial

By Beth Sandy, MSN, CRNP, FAPO

ASCO 2025 - Non-Small Cell Lung Cancer

The SOHO-01 trial highlights the manageable safety and promising efficacy of sevabertinib (BAY 2927088) in patients with pretreated or untreated HER2-mutant NSCLC. Read More ›

Videos

Safety of Imlunestrant in ER-Positive, HER2-Negative Advanced Breast Cancer: EMBER-3 Trial Results

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

EMBER-3 trial findings position imlunestrant monotherapy or in combination with abemaciclib as a promising, safe and effective oral therapeutic option for treating estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Read More ›

Videos

Promising Results for Elacestrant Combinations in ER-Positive, HER2-Negative Metastatic Breast Cancer: ELEVATE Trial Findings

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

Elacestrant in combination with ribociclib or everolimus demonstrates promising efficacy and manageable safety in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who experienced disease progression after endocrine therapy plus CDK4/6 inhibitors, Read More ›

Videos

SERENA-6 Phase 3 Trial: Camizestrant Plus CDK4/6 Inhibitor for ctDNA-Guided Treatment of ESR1 Mutations in HR-Positive, HER2-Negative Advanced Breast Cancer

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

The SERENA-6 trial reveals camizestrant's potential to improve outcomes in hormone receptor (HR)-positive, HER2-negative breast cancer by utilizing circulating tumor DNA (ctDNA)-guided therapy towards ESR1 mutations before disease progression. Read More ›

Videos

Patient-Reported Outcomes of Imlunestrant in EMBER-3 Trial for ER-Positive, HER2-Negative Advanced Breast Cancer

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

Patient-reported outcomes from EMBER-3 demonstrate that imlunestrant improves global health status/quality of life and physical function in patients with ESR1 mutations in estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Read More ›

Wrap-Up

Phase 2 Study of BEBT-209 Plus Gemcitabine and Carboplatin in Metastatic TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of BEBT-209 with gemcitabine and carboplatin showed promising efficacy and a tolerable safety profile in metastatic triple-negative breast cancer (TNBC). Read More ›

American Society of Clinical Oncology (ASCO)

Page 2 of 33